Compare GCTS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCTS | MAIA |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | 126 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.5M | 77.1M |
| IPO Year | N/A | 2022 |
| Metric | GCTS | MAIA |
|---|---|---|
| Price | $3.38 | $1.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 7.5M | 547.8K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,052.30 | N/A |
| Revenue Next Year | $140.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $0.87 |
| 52 Week High | $3.57 | $3.19 |
| Indicator | GCTS | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 81.08 | 47.43 |
| Support Level | $1.24 | $1.24 |
| Resistance Level | N/A | $1.46 |
| Average True Range (ATR) | 0.40 | 0.08 |
| MACD | 0.19 | 0.00 |
| Stochastic Oscillator | 89.78 | 33.19 |
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness. Geographically, operates in South Korea and the United States, with maximum revenue from the USA.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.